# Virax Biolabs Group Limited (VRAX)

Source: https://www.quantisnow.com/company/VRAX
Generated: 2026-11-19T02:34:42.628Z

- Ticker: VRAX
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: In Vitro & In Vivo Diagnostic Substances
- IPO year: 2022
- SEC CIK: 0001885827
- Website: https://viraxbiolabs.com

## About

Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits, and med-tech and PPE products for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company offers rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name; and med-tech and PPE products, such as employee protection equipment products under the ViraxCare brand name. It also distributes nebulizing machines and smart wearable devices that alert employees to help them follow social distance guidelines. In addition, the company operates an online platform that sells ViraxClear and ViraxCare products. It serves clinics, pharmacies, laboratories, hospitals, and other groups, as well as corporations, employees, and individual consumers. The company operates in Europe, South America, the Asia Pacific, Sub-Saharan Africa, and internationally. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. The company was incorporated in 2021 and is based in London, the United Kingdom.

## Latest VRAX news and filings

- 2026-11-18 12:32 UTC [SEC Form 6-K] [SEC Form 6-K filed by Virax Biolabs Group Limited](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-virax-biolabs-group-limited-6798022)
- 2026-11-13 21:20 UTC [SEC Form 6-K] [SEC Form 6-K filed by Virax Biolabs Group Limited](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-virax-biolabs-group-limited-6790792)
- 2026-10-29 11:40 UTC [SEC Form 6-K] [SEC Form 6-K filed by Virax Biolabs Group Limited](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-virax-biolabs-group-limited-6762552)
- 2026-10-29 11:30 UTC [Leadership Update] [Virax Biolabs Appoints Three Distributors for ImmuneSelect Research Products in Mainland China](https://www.quantisnow.com/insight/virax-biolabs-appoints-three-distributors-for-immuneselect-research-products-in-6762517)
- 2026-10-21 12:12 UTC [SEC Form 3] [SEC Form 3 filed by Virax Biolabs Group Limited](https://www.quantisnow.com/insight/sec-form-3-filed-by-virax-biolabs-group-limited-6753028)
- 2026-10-09 20:15 UTC [SEC Form 6-K] [SEC Form 6-K filed by Virax Biolabs Group Limited](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-virax-biolabs-group-limited-6742931)
- 2026-09-04 20:10 UTC [SEC Form 424B5] [SEC Form 424B5 filed by Virax Biolabs Group Limited](https://www.quantisnow.com/insight/sec-form-424b5-filed-by-virax-biolabs-group-limited-6706794)
- 2026-09-04 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Virax Biolabs Group Limited](https://www.quantisnow.com/insight/sec-form-effect-filed-by-virax-biolabs-group-limited-6706128)
- 2026-09-02 21:23 UTC [Amendment: SEC Form F-3/A filed by Virax Biolabs Group Limited](https://www.quantisnow.com/insight/amendment-sec-form-f-3a-filed-by-virax-biolabs-group-limited-6703698)
- 2026-08-26 20:30 UTC [SEC Form 6-K] [SEC Form 6-K filed by Virax Biolabs Group Limited](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-virax-biolabs-group-limited-6695762)
- 2026-08-18 11:30 UTC [SEC Form 6-K] [SEC Form 6-K filed by Virax Biolabs Group Limited](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-virax-biolabs-group-limited-6685849)
- 2026-07-31 11:44 UTC [SEC Form 6-K] [SEC Form 6-K filed by Virax Biolabs Group Limited](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-virax-biolabs-group-limited-6657155)
- 2026-07-24 20:20 UTC [SEC Form F-3 filed by Virax Biolabs Group Limited](https://www.quantisnow.com/insight/sec-form-f-3-filed-by-virax-biolabs-group-limited-6648405)
- 2026-07-16 11:31 UTC [SEC Form 6-K] [SEC Form 6-K filed by Virax Biolabs Group Limited](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-virax-biolabs-group-limited-6639003)
- 2026-07-16 11:30 UTC [Virax Biolabs' CEO James Foster Provides Shareholder Update Following Fiscal 2026 Annual Report and Fosun Diagnostics Commercial Supply Agreement](https://www.quantisnow.com/insight/virax-biolabs-ceo-james-foster-provides-shareholder-update-following-fiscal-6638993)
- 2026-07-10 20:06 UTC [SEC Form 6-K] [SEC Form 6-K filed by Virax Biolabs Group Limited](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-virax-biolabs-group-limited-6634091)
- 2026-07-10 20:05 UTC [Public Offering] [Virax Biolabs Group Limited Announces Closing of Exercise of Preferred Investment Options for $3.3 Million Gross Proceeds](https://www.quantisnow.com/insight/virax-biolabs-group-limited-announces-closing-of-exercise-of-preferred-6634066)
- 2026-07-10 16:17 UTC [These Companies Just Dropped Major Growth Catalysts](https://www.quantisnow.com/insight/these-companies-just-dropped-major-growth-catalysts-6633845)
- 2026-07-09 17:35 UTC [Virax Biolabs Group Limited Announces Exercise of Preferred Investment Options for $3.3 Million Gross Proceeds](https://www.quantisnow.com/insight/virax-biolabs-group-limited-announces-exercise-of-preferred-investment-options-6632822)
- 2026-07-09 11:33 UTC [SEC Form 6-K] [SEC Form 6-K filed by Virax Biolabs Group Limited](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-virax-biolabs-group-limited-6632363)
- 2026-07-09 11:30 UTC [Virax Biolabs Signs Multi-Country Commercial Supply Agreement with Fosun Diagnostics](https://www.quantisnow.com/insight/virax-biolabs-signs-multi-country-commercial-supply-agreement-with-fosun-diagnostics-6632355)
- 2026-07-03 00:25 UTC [SEC Form 20-F filed by Virax Biolabs Group Limited](https://www.quantisnow.com/insight/sec-form-20-f-filed-by-virax-biolabs-group-limited-6627075)
- 2026-06-24 20:46 UTC [SEC Form 6-K] [SEC Form 6-K filed by Virax Biolabs Group Limited](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-virax-biolabs-group-limited-6614462)
- 2026-06-24 13:00 UTC [Virax Biolabs Group Limited Announces 1-for-25 Share Consolidation](https://www.quantisnow.com/insight/virax-biolabs-group-limited-announces-1-for-25-share-consolidation-6613791)
- 2026-06-12 13:24 UTC [SEC Form 6-K] [SEC Form 6-K filed by Virax Biolabs Group Limited](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-virax-biolabs-group-limited-6599729)
- 2026-05-26 11:33 UTC [SEC Form 6-K] [SEC Form 6-K filed by Virax Biolabs Group Limited](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-virax-biolabs-group-limited-6571245)
- 2026-05-26 11:30 UTC [Virax Biolabs Reports Positive Early Clinical Data for ViraxImmune™ in Long COVID and Related Post-Acute Infection Syndromes](https://www.quantisnow.com/insight/virax-biolabs-reports-positive-early-clinical-data-for-viraximmune-in-6571236)
- 2026-05-22 20:25 UTC [SEC Form 6-K] [SEC Form 6-K filed by Virax Biolabs Group Limited](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-virax-biolabs-group-limited-6570017)
- 2026-05-15 15:14 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by Virax Biolabs Group Limited](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-virax-biolabs-group-6556416)
- 2026-04-14 12:43 UTC [SEC Form 6-K] [SEC Form 6-K filed by Virax Biolabs Group Limited](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-virax-biolabs-group-limited-6498958)
- 2026-04-14 11:34 UTC [Virax Biolabs' CEO James Foster Outlines Strategic Priorities and Near-Term Milestones in Letter to Shareholders](https://www.quantisnow.com/insight/virax-biolabs-ceo-james-foster-outlines-strategic-priorities-and-near-term-6498682)
- 2026-04-10 20:15 UTC [SEC Form 6-K] [SEC Form 6-K filed by Virax Biolabs Group Limited](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-virax-biolabs-group-limited-6496299)
- 2026-03-31 19:15 UTC [SEC Form 3] [SEC Form 3 filed by new insider Haight Nelson M](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-haight-nelson-m-6478779)
- 2026-03-31 11:34 UTC [Virax Biolabs Achieves ISO Certifications, Laying Foundation for Regulated IVD Development and U.S. Clinical Validation](https://www.quantisnow.com/insight/virax-biolabs-achieves-iso-certifications-laying-foundation-for-regulated-ivd-6477896)
- 2026-03-20 14:43 UTC [SEC Form 3] [SEC Form 3 filed by new insider Mccracken Nigel William](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-mccracken-nigel-william-6462872)
- 2026-03-18 21:09 UTC [SEC Form 6-K] [SEC Form 6-K filed by Virax Biolabs Group Limited](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-virax-biolabs-group-limited-6458789)
- 2026-03-18 20:05 UTC [SEC Form 3] [SEC Form 3 filed by new insider Foster James Alexander Cunliffe](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-foster-james-alexander-6457665)
- 2026-03-18 20:05 UTC [SEC Form 3] [SEC Form 3 filed by new insider Norton Evan Michael](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-norton-evan-michael-6457654)
- 2026-03-18 20:05 UTC [SEC Form 3] [SEC Form 3 filed by new insider Davis Jason](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-davis-jason-6457644)
- 2026-03-18 20:05 UTC [SEC Form 3] [SEC Form 3 filed by new insider Miller Iain David](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-miller-iain-david-6457638)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/VRAX
- Earnings history: https://www.quantisnow.com/earnings/VRAX
- Dividend history: https://www.quantisnow.com/dividends/VRAX
- Insider transactions: https://www.quantisnow.com/insiders/VRAX
- Options chain: https://www.quantisnow.com/options/VRAX
- SEC 8-K filings only: https://www.quantisnow.com/company/VRAX/8-k
- RSS and alerts for VRAX: https://www.quantisnow.com/docs/rss-feeds.md
